Humanis R&D Center, recognized as one of the top five pharmaceutical R&D centers encouraged by the Republic Of Türkiye Ministry of Industry and Technology, is celebrating its 10th anniversary.
Over these 10 years, the Humanis R&D Center has achieved full compliance with QbD (Quality by Design), EMA (European Medicines Agency), and ICH (International Council for Harmonisation) regulations, contributing approximately 200 products and over 100 molecules to Turkish medicine.
Humanis CEO Yunus Sancak emphasized that the greatest contribution to the R&D center’s progress over the decade belongs to their colleagues, highlighting that people are the most important asset for Humanis. He underscored their success in maintaining the highest quality standards, both nationally and internationally, by working with competent and right individuals.
Yunus Sancak stated, “In this ten-year period, we have completed the licensing processes for 200 drugs and developed over 100 molecules, steadfastly progressing towards our goal of becoming a trusted and beloved healthcare brand in Turkish medicine.”
Sancak added: “Our human resources are the most important asset for Humanis. We see our colleagues as our companions, basing our relationships on trust and respect. Each of their presence and efforts is highly valuable. Thanks to our institutional culture built on these values, we have been working with competent and right individuals at Humanis and in our R&D center for years. Throughout this 10-year journey of research and development, we have done our utmost, reaching an indispensable position in Turkish medicine.”
